Literature DB >> 23428794

Serial infusions of low-dose ketamine for major depression.

Keith G Rasmussen1, Timothy W Lineberry, Christine W Galardy, Simon Kung, Maria I Lapid, Brian A Palmer, Matthew J Ritter, Kathryn M Schak, Christopher L Sola, Allison J Hanson, Mark A Frye.   

Abstract

BACKGROUND: Single infusions of ketamine have been used successfully to achieve improvement in depressed patients. Side effects during the infusions have been common. It is not known whether serial infusions or lower infusion rates result in greater efficacy.
METHODS: Ten depressed patients were treated with twice weekly ketamine infusions of ketamine 0.5 mg/kg administered over 100 min until either remission was achieved or four infusions were given. Side effects were assessed with the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS). Patients were followed naturalistically at weekly intervals for four weeks after completion of the infusions.
RESULTS: Five of 10 patients achieved remission status. There were no significant increases on the BPRS or YMRS. Two of the remitting patients sustained their improvement throughout the four week follow-up period.
CONCLUSIONS: Ketamine infusions at a lower rate than previously reported have demonstrated similar efficacy and excellent tolerability and may be more practically available for routine clinical care. Serial ketamine infusions appear to be more effective than a single infusion. Further research to test relapse prevention strategies with continuation ketamine infusions is indicated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428794     DOI: 10.1177/0269881113478283

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  64 in total

1.  Ketamine for depression: evidence, challenges and promise.

Authors:  Carlos A Zarate; Mark J Niciu
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

Review 2.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

Review 3.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

Authors:  P Molero; J A Ramos-Quiroga; R Martin-Santos; E Calvo-Sánchez; L Gutiérrez-Rojas; J J Meana
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

Review 4.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

5.  Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.

Authors:  Eric J Lenze; Nuri B Farber; Evan Kharasch; Julie Schweiger; Michael Yingling; John Olney; John W Newcomer
Journal:  World J Biol Psychiatry       Date:  2016-02-26       Impact factor: 4.132

6.  "Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?"

Authors:  Laili Soleimani; Alison Welch; James W Murrough
Journal:  Curr Treat Options Psychiatry       Date:  2015-10-16

Review 7.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

8.  Current Trends in Identifying Rapidly Acting Treatments for Depression.

Authors:  Dawn F Ionescu; George I Papakostas
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-15

Review 9.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

Review 10.  The promise of ketamine for treatment-resistant depression: current evidence and future directions.

Authors:  Kaitlin E DeWilde; Cara F Levitch; James W Murrough; Sanjay J Mathew; Dan V Iosifescu
Journal:  Ann N Y Acad Sci       Date:  2015-02-03       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.